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Introduction
The DSM-III classification of psychiatric disorders
of 1980 was a hoped-for improvement in nosology,
as it sought an operationally defined system based
on overt behaviors. In this and subsequent itera-
tions, the core mood disorder became a monolithic
major depressive disorder with modifiers for
differences in severity (e.g. psychotic or not), and
for circumstances presumed to have clinical signi-
ficance (e.g. abnormal bereavement, postpartum
depression). The traditional concept of manic-
depression was separated into unipolar and bipo-
lar categories. The well-established concept of
melancholia was discarded, and laboratory tests
were excluded from the criteria (1).
The diagnostic criteria that were formulated,
however, are imprecise, inadequate for treatment
decisions, and do not assure homogeneous popu-
lations in clinical trials, thereby missing opportun-
ities to define the specific actions that are sought in
new treatments. A cogent example is the evaluation
of antidepressants in the STAR*D study (2). In a
US government-supported multi-site collaborative
effort, out-patients meeting criteria for non-psy-
chotic unipolar depression were first treated with
citalopram, and 30% responded. The remaining
patients were offered one of three antidepressant
agents, to which an additional one-quarter respon-
ded, leaving half the subjects without symptomatic
relief in repeated trials. The study does not offer
effective guidelines for subject selection for these
medications.
The out-patient population sample was hetero-
geneous. Although the severity of the illness was
rated as moderate (HDRS (Hamilton Depression
Rating Scale)17 score 19 ± 7.3), 17% reported
suicide attempts, 76% suffered recurrent illnesses,
the duration of the present episode averaged
30 months, the lifelong duration of illness was
17 years, and the subjects reported an average of
seven episodes of illness. Features of anxious
depression were recorded in 44% and atypical
depression in 20%. The criteria for major depres-
sion failed to distinguish those with characterolog-
ical and social influences on their illness from those
with a distinctive biological basis. The heterogeneity
of the sample is one explanation for theweak results.
Guidelines to establish diagnostic validity for a
clinical condition, and therefore maximize homo-
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geneity, were offered by Robins and Guze (3). They
defined a clinical syndrome as the delineation of
characteristic signs and symptoms, supported by
laboratory tests or biologic markers, with a char-
acteristic clinical course and response to treat-
ments. We applied these principles in an earlier
assessment of catatonia. We described the charac-
teristic motor signs in examination and rating
scales, validated the syndrome by a lorazepam
response test, and successfully treated patients with
sedative anticonvulsant medications and convul-
sive therapy (4, 5).
Using a similar method, we propose the
replacement of the present potpourri of mood
disorders in DSM-III and DSM-IV that serves
our patients poorly. We demarcate a prototypic
syndrome of melancholia by specific psychopa-
thology, laboratory tests, and effective treatments
(1). The remaining mood disorders are categor-
ized in a non-homogeneous class of non-melan-
cholic disorders, awaiting the definition of other
distinctive syndromes using the same principles.
An example is offered by the analysis of atypical
depression by Stewart et al. (6) in this issue (see
pp. 58–71).
The concept of melancholia
A syndrome of madness with bodily causes has
been clinically recognized for centuries. Except for
two periods in Western history – the Middle Ages
in Europe when church teachings dominated
Western thought and in the 20th century when
psychoanalytic notions usurped psychiatric think-
ing – melancholia was identified as a distinct
periodic mood disorder with both manic and
depressive phases and without progressive deteri-
oration (1, 7–12). In 20th century classifications,
psychoanalysts defined psychiatric illnesses as
being of mental, not brain origin, with depressive
and manic periods as reactions to personal
experience. The classifications in DSM-I and
DSM-II were based on this philosophy.
By the late 1960s, however, it was no longer
considered acceptable to treat depressed patients as
if they were all suffering from a single condition, as
treatments were found to be effective for some
patients and not for others (13–16). An assessment
of 33 studies of medication treatments for depres-
sion, for example, could not find a diagnostic
formulation that had predictive strength (17). The
poor reliability of the existing classifications was
clearly demonstrated in the strikingly different
diagnostic conclusions reached by American and
British psychiatrists examining the same patients
(18, 19).
Melancholia has been ignored in each subse-
quent DSM revision. To acknowledge the many
conditions that could be described, DSM-III listed
265 disorders, increased to 292 in DSM-IIIR, and
to 295 in DSM-IV (20). A similar increase in the
number of putative disorders is found in the ICD
classification system (21).
From major depression to melancholia
In our present system of diagnosis, we identify
patients who meet criteria for major depression by
cross-sectional, unweighted features. Persons who
feel saddened by life events or who are disgruntled
and unhappy by virtue of life’s vicissitudes or by
their personality traits meet criteria for major
depression if these moods are associated with
decreased energy or interest. Their inclusion
within the class of major depression confounds
the results of clinical treatment trials and laborat-
ory searches for an understanding of mood disor-
ders. The large numbers of placebo responders in
such samples attest to the need for a higher
threshold to identify depressed persons that war-
rant somatic treatment (1, 2).
Quality of mood (unremitting apprehension and
sadness), psychomotor disturbance (agitation or
bradykinesia), multiple vegetative signs, and
psychosis are essential elements in defining melan-
cholia. The present psychiatric classification does
not require these features in the diagnosis of a
depressive illness.
Abnormal neuroendocrine tests and disturbed
sleep EEG measures are common in melancholia.
Hypercortisolemia is prominent, particularly when
the melancholic patient is agitated or psychotic.
When measured by the dexamethasone suppression
test (DST), cortisol functions are abnormal when
patients are ill, normalize with remission, and
became abnormal again in relapse (1, 22, 23).
Similar findings, although less robust, are seen in
thyroid function tests and sleep EEG measures (1).
Although developed heuristically and without a
central theory, these tests buttress the melancholia
diagnosis. They are equally useful (e.g. similar in
sensitivity and specificity) to the EEG, brain
imaging, and serum prolactin levels in defining a
seizure disorder.
In the psychopathological literature, melancho-
lia is consistently described as a severe illness of
acute onset with unremitting moods of apprehen-
sion and gloom, psychomotor disturbance, and
vegetative signs. Psychosis, intermittent mania, and
suicide intent are prominent features. A compelling
picture of melancholia is offered by Falret in
describing a circular insanity:
Resurrecting melancholia
15
At the commencement of this phase… the patients begin
to withdraw and now speak only rarely. Sometimes they
express remorse over their previous condition…
remaining all alone and motionless… they are now
meek, and their humility may go so far as for them to
refuse treatment in the belief that they do not deserve it.
This despondency becomes more pronounced daily…
[and] the patient is transformed into a statue… were he
not coaxed to eat, the patient would not bother to seek
food….
The thought processes and his movements are very slow;
rarely this may result in complete cessation of all intel-
lectual activity…. The face is pale; the features sag,
suggesting dejection rather than anxiety…. Appetite is
decreased, and the patient eats little; digestion is equally
slow and defecation is laborious.
Nevertheless, there are a certain number of patients who
present with specific preoccupations, among which we
have noticed ideas of humility, of ruin, of being poi-
soned, or of guilt. (24)
We propose to reinstitute the definition of
melancholia, set a duration criterion of two
weeks, and add as secondary criteria the associated
laboratory findings of dexamethasone non-sup-
pression of cortisol, high nighttime cortisol levels,
or decreased REM latency or other characteristic
sleep abnormalities (Table 1).
Applying such criteria to the entities described in
DSM-IV finds that patients with diverse syn-
dromes as presently defined meet the criteria for
melancholia (Table 2). Patients with mood disor-
ders who do not meet criteria for melancholia
comprise a large heterogeneous population best
labeled for the present as within the non-melan-
cholic mood disorders.
The proposed criteria for melancholia have face
validity for high specificity. They make false-
positive diagnoses unlikely, and maximize the
identification of homogeneous population samples
for clinical trials and studies of pathophysiology.
They meet the three principal criteria for a clinical
syndrome delineated by Robins and Guze (3).
Verification by psychopathology
Almost all empirical studies over four decades
report major depression as encompassing different
patient groupings with between 20% and 70% of
the samples described as psychotic, melancholic, or
endogenously depressed. The less homogeneous
groups are younger, less severely ill, exhibit
abnormal trait behavior, and meet criteria for
anxiety disorder or atypical depression (1).
The strongest negative study is that of Kendell
(25, 26) who used data from hospital discharge
forms collected by trainee psychiatrists at the
Maudsley Hospital between 1949 and 1963. Ken-
dell failed to find a bimodal distribution of patient
characteristics and concluded that depressive dis-
orders were best viewed as a continuum. Although
the Maudsley report form did not include items
needed to delineate melancholia and the inter-rater
reliability of the raters is unknown, we looked
carefully at the two factors that were delineated
(Table 3). Kendell clearly identified a psychotic
depression group that closely matches criteria for
the melancholia syndrome.
Over 70 other studies in the past quarter century
refute Kendell’s conclusion and support the finding
of a melancholia syndrome. For example,
Matussek et al. (27), Maes et al. (28), Parker and
his coworkers (12, 29), Sullivan et al. (30) and
Ambrosini et al. (31) identify clusters of depressed
patients with distinct qualities of mood, loss of
reactivity, social withdrawal, loss of energy,
psychomotor abnormalities of paucity of speech
and movement, vegetative signs and disturbances
Table 1. Proposed diagnostic criteria for melancholia (1) (all must be present)
A. An episode of illness with reduced functioning characterized by an unremitting
mood of apprehension and gloom that compromises normal daily activities and
persists for at least 2 weeks
B. Psychomotor disturbance as agitation, retardation (including stupor and cata-
tonia), or both
C. Vegetative signs (at least two).
D. At least one of the following:
Abnormal dexamethasone suppression or dexamethasone-suppressed cortico-
tropin-releasing hormone test (DEX/CRH); high nighttime cortisol levels
Decreased REM latency or other sleep abnormalities
Table 2. Proposed inclusions in melancholia









Table 3. Kendell's two-depression factors







Gross disturbance in food intake
Gross disturbance in weight
Severe insomnia
Retarded activity








in circadian rhythms, and suicidal thoughts. Such
patients have a poor prognosis for marginally
effective interventions and require intensive bio-
logically based treatments (1, 11, 27–31).
Verification by laboratory tests
Few laboratory tests are associated with abnormal
behaviors. Aside from serological tests for syphilis
and systemic examinations for infection or meta-
bolic error, the EEG has been the most helpful test
of a behavior syndrome. Single inter-ictal record-
ings exhibit seizure rhythms in 50–55% of patients
with well-defined epilepsy. Two recordings increase
sensitivity to 92% (32). It is difficult to conceive of
a medical examination that considers epilepsy
without examining EEG recordings. This standard
is useful in discussing the role of laboratory tests in
melancholia.
Hypercortisolemia is a feature of pituitary and
adrenal pathology. In the search for normative
standards, highly abnormal levels were found in
melancholic depressed patients. The finding stimu-
lated an interest in cortisol physiology and led to
the development of the DST (22).
Elevated levels of cortisol, loss of diurnal rhyth-
micity, and impaired suppression of cortisol by
dexamethasone were well documented in severely
depressed patients, especially in those with weight
loss, agitation, suicide risk, and psychosis. With
successful antidepressant treatment, plasma corti-
sol levels fell to the levels of normal subjects. Carroll
concluded that: The suppression test distinguished
clearly between the depressed and the control
patients who could not be distinguished simply on
the basis of their diurnal plasma cortisol levels (33).
By 1976, the DST was established as a measure
of severe depression. Greater Hypothalmic-Pitui-
tary-Adrenal (HPA) activity before dexamethasone
and less complete HPA suppression following its
administration was reported in 42 patients with
endogenous depression compared with 42 patients
with other psychiatric disorders. Patients with two
or more abnormal cortisol values after dexameth-
asone were correctly identified as being endogen-
ously depressed (34).
By 1981, the DST was validated …as a test for
the diagnosis of melancholia (endogenous depres-
sion) in 438 patients using a cut-off level of 5 lg/dl
plasma cortisol after 1 mg dexamethasone admin-
istration (35). Two blood samples taken at 16.00
and 21.00 h after dexamethasone administered at
21.00 h the night before detected 98% of the
abnormal test results. This version of the DST
identified melancholic patients with a sensitivity of
67% and a specificity of 96%.
Doing the test properly, however, is difficult. Each
laboratory needs to establish local normative stand-
ards. Monitoring plasma dexamethasone levels is
necessary as the systemic response is sensitive to
dexamethasone dosage and serum levels. Preg-
nancy, end-stage dementia, substantial weight loss,
and interference from other agents (e.g. steroids,
some anticonvulsants) affect the test and are neces-
sarily considered in assessing its results.
TheDSTwaswidely recognized as a statemarker,
but it was also examined for its correlation with
clinical diagnoses. The DST is commonly abnormal
in patients with delusional (psychotic) depression. A
meta-analysis of 14 studies comparing DST results
in psychotic and non-psychotic depressed patients
found the non-suppression rate to be substantially
higher in psychotic depressed patients (36). Patients
with schizophrenia typically do not show abnormal
cortisol levels, arguing that the high levels are
characteristic not of psychosis, but ofmooddisorder
(1).
The frequency of non-suppression in manic
patients varied from 0% to 70% with the highest
frequency in mixed bipolar disorder (1).
Depressed patients with abnormal DST have a
higher risk for suicide. In a 15-year follow-up study
the suicide risk in those with an abnormal DST was
27% compared with 3% among patients with a
normal DST. A review of 101 patients re-examined
over 2 years confirmed the higher risk for suicide
and indicated hospitalization for suicide risk in
those with abnormal DST. Patients with abnormal
cortisol metabolism are more likely to make suicide
attempts (1).
DSM-III was introduced at the time that the
DST was being assessed, and its role as a diagnos-
tic test was examined. By 1985, reviewers conclu-
ded that:
The sensitivity of the DST in major depression is limited
(about 44% in over 5000 cases) but is higher in psychotic
affective disorders and mixed manic-depressive states
(67% to 78%). The high specificity of the DST vs con-
trol subjects (over 90%) is not maintained vs other
psychiatric disorders (77% specificity overall), and acute
distress may contribute to non-suppression of cortisol
(37).
These authors concluded:
The test may have power in differentiating severe
melancholic depression, mania, or acute psychosis from
chronic psychosis (87% specificity) or dysthymia (77%
specificity).
The DST was discarded from the clinic and in
psychiatric research. Yet, as recently as 1996, Rush
et al. (38), in a large study of patients meeting
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criteria for both unipolar and bipolar depression
by RDC criteria, reported cortisol non-suppression
in 35% of endogenously ill out-patients and in 9%
of non-endogenously ill. Among in-patients, non-
suppression was found in 62% and 19% respect-
ively. The sensitivity was assessed as 40%, the
specificity at 90%. In placebo responders, 10% are
DST non-suppressors and 70% are suppressors (1).
The weight of the evidence indicates that the DST
is a valid test of the presence of a severe depressive
mood disorder, especially in those meeting criteria
for psychotic and melancholic depression. Like the
EEG in seizure disorders, measures of cortisol
physiology are not simple tests, but offer a useful
criterion in defining an illness. A positive test assures
the diagnosis; a negative test encourages further
assessment. Additional measures as the thyroid
stimulating hormone (TSH) response to thyrotro-
pin-releasing hormone (TRH) and the sleep EEG
offer further validation criteria (1).
The dexamethasone-suppressed corticotropin-
releasing hormone (DEX/CRH) measure of cort-
isol physiology improves sensitivity (1). It took
more than half a century of experience from the
descriptions of the human EEG by Hans Berger in
the 1930s to achieve the quantitative digital com-
puter and video-assisted EEG diagnoses of today.
Improvements in measures of cortisol and neuro-
endocrine physiology offer a similar opportunity to
design better laboratory test criteria for melancho-
lia.
Although less well codified, studies of EEG sleep
characteristics consistently find greater abnormal-
ities in hospitalized, more severely ill patients
exhibiting features of endogenous depression.
Sleep studies, are difficult to apply clinically, but
have heuristic research value in defining a melan-
cholic depression (1).
Verification by treatment
The development of highly efficient antibiotics for
bacterial infections, and vitamin and hormone
replacements for dietary and hormone deficiencies
verified a clinical diagnosis. The astonishing effic-
acy of ECT in remitting melancholia also supports
the diagnosis. Melancholia remits with greater than
90% efficiency within 3 weeks with bilateral ECT
(39, 40). Critics will note that ECT is as effective in
delirious mania and catatonia as it is in melancho-
lia, and will argue that these actions are too broad
to verify a diagnosis. Patients with mania, how-
ever, almost always have episodes of depressive
illness. Over their life-time, they experience depres-
sion more often than episodes of mania. Catatonia
is commonly defined in patients with mood disor-
ders, and almost all patients in a melancholic or
manic episode exhibit some features of catatonia
(e.g. automatic obedience, ambitendency) (3, 4).
Furthermore, the broad action of penicillin in
bacterial and spirochaetal infections does not
invalidate its specificity for either condition.
The multi-site collaborative study of continu-
ation ECT and continuation pharmacotherapy
(known as CORE) used bilateral ECT in patients
meeting rigorous criteria for unipolar major
depression. It reported an overall remission rate
of 87% among treatment completers, with an
astonishing 95% rate for the 30% of patients
identified as psychotic depressed based on Struc-
tured Clinical Interview for DSM-IV (SCID)
criteria (41, 42). Although characterized as meeting
criteria for major depression, the major part of the
CORE sample meets the criteria for melancholia
based on severity of the mood disorder, high
incidence of psychosis and suicide risk, and failure
to respond to multiple medication trials. A post-
hoc analysis of the items rated on the Hamilton
Depression Rating Scale (HAMD)24, SCID, and
Inventory of Deppressive Symptomatology (IDS)
scales finds that more than 60% meet symptom
criteria for melancholia.
Lesser remission rates of 50–60% with ECT in
hospitalized unipolar depressed patients are still
reported, but are understood to result from inef-
ficient treatment methods (43). Successful ECT
also reverses the hormone imbalances seen in
depressive illness. Carroll (33) reported a normal-
ized DST in five patients treated with ECT, with
reversion to abnormality heralding relapse. The
same reversal in other hormone tests has been
observed and these experiences are the basis for a
neuroendocrine explanation of the mode of action
of induced seizures in melancholia (39, 44).
Broad pharmacodynamic spectrum antidepres-
sants are more effective in melancholic than in non-
melancholic patients. Lithium moderates abnormal
mood and reduces suicidal drive, and is the most
effective augmenting agent in the treatment of
acute depressive illness when the patient is melan-
cholic. It is efficient as continuation therapy for
melancholic patients, especially when combined
with the tricyclic nortriptyline (1, 11, 42).
Tricyclic antidepressants effectively relieve mel-
ancholic depression but do so less efficiently than
ECT. The imbalance is seen in the relative ineffi-
cacy of TCA in psychotic melancholic patients
where remission rates are low (1, 11).
Although the more recently introduced selective-
serotonin reuptake inhibitor and similar agents are
widely recommended as the first agents in treat-
ment algorithms for major depression, their overall
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30–40% remission rates differ only minimally from
placebo (45). They are much less effective in
hospitalized patients, those more likely to be
suffering from melancholic depression. These
experiences speak against their specificity in the
pathophysiology of melancholia. By contrast,
the extraordinary efficacy of ECT in inducing
remission, reducing suicide risk, and reversing
endocrine abnormalities marks the mechanism of
action of induced seizures as an essential target for
studies of the pathophysiology of melancholia (44).
Unipolar–bipolar distinction
Patients with mood disorder are now dichotomized
by a history of manic or hypomanic episodes into
recurrent depressive or bipolar disorder. When
depressive illness is grouped by criteria of melan-
cholia, however, the unipolar/bipolar dichotomy
fails. No characteristic psychopathology separates
the melancholic patient with a history of mania or
hypomania from one without such a history. The
illnesses are commonly recurrent and in succeeding
episodes 70% of patients initially classified as
bipolar disorder meet criteria for major depression;
and, in the course of a major depressive illness,
10% exhibit episodes of mania and over half
exhibit features of mania when depressed (1).
In an extensive analysis of unipolar and bipolar
depression examining the course, epidemiology,
family history, physiological measures, incidence
of clinical signs of anxiety, anger, psychomotor
agitation, mood lability, sleep time, and pain
sensitivity Goodwin and Jamison (11) were
unable to identify distinguishing characteristics.
They found the breadth of differences and hetero-
geneity impressive, and yet they concluded:
Taken together, the data suggest that they (mania,
depression) are best considered as two subgroups of
manic-depressive illness rather than separate and dis-
tinct illnesses. The available data also support a con-
tinuum model, with pure bipolar illness at one end and
unipolar illness at the other.
Others also fail to find psychopathological separ-
ation points for the two conditions (46–48). Histor-
ically, the two conditions were identified as facets of
a condition of circular insanity by French psycho-
pathologists Falret (24) and Baillarger (49). Their
descriptions were adopted by Kraepelin (50) in the
concept of manic-depressive psychosis that has been
a mainstay of classification until DSM-III. Demar-
cating melancholia as a defined depressive mood
disorder encourages the earlier views of a single
psychopathology for mania and depression.
In conclusion, the present classification of mood
disorders is arbitrary, divided into a multitude of
presumed disorders with imprecise criteria. The
formulations do not encourage effective therapy or
definitive research. Patients meeting criteria for
single major depression are said to respond to the
same treatment algorithm, with the more severe
needing higher doses or drug combinations, but
not different approaches. The putative unipolar
and bipolar disorders are said to require different
algorithms.
The evidence is the opposite: melancholia can be
distinguished from other depressive mood disorders
by its characteristic psychopathology. The unipolar/
bipolar dichotomy is not supportedwhen the criteria
for melancholia are used to classify depressive
illness. The treatment algorithm for melancholia
differs from that of non-melancholic depressions,
but the treatment algorithms for melancholia with
or without mania are similar. We find compelling
evidence that hypercortisolemia is characteristic of
severely ill depressed patients, and tests of this
hormone (and other hormones) should be consid-
ered in the classification and the management of
patients with depressive mood disorders. Various
treatments – lithium, tricyclic antidepressants, and
ECT – effectively relieve both the depressive and
manic phases of the syndrome. The expert treatment
algorithms thus require substantial revision if they
are to claim to be evidence based.
We propose the demarcation of a syndrome of
melancholia as the best opportunity to develop
homogeneous study populations, more effective
treatment algorithms, better understanding of the
pathophysiology of mood disorders, and reducing
the social burden of therapy-resistant depressed
patients.
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